- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04993586
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
A Randomized, Open-label, Uncontrolled, Phase I/II Study to Assess Safety and Immunogenicity of Two or Three Dosing of Intramuscular/Intradermal AG0302-COVID19
Study Overview
Status
Conditions
Detailed Description
This is a Phase I/II, multi-center, randomized, open-label, uncontrolled trial. Approximately 400 healthy volunteers, male or female, aged 18 years or older, will be randomized to one of the following five groups:
[IM Groups] Group A: Vaccination 2 mg, three times at 2-week intervals (n = 80) Group B: Vaccination 4 mg, twice at 4-week intervals (n = 80) Group C: Vaccination 8 mg, twice at 4-week intervals(n = 80)
[ID Groups] Group D: Vaccination 1 mg, three times at 2-week intervals (n = 80) Group E: Vaccination 1 mg, twice at 4-week intervals (n = 80)
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Osaka, Japan, 532-0003
- Medical Corporation Heishinkai OPHAC Hospital
-
-
Chiba
-
Narita, Chiba, Japan, 286-8520
- Iuhw Narita Hospital
-
-
Osaka
-
Suita, Osaka, Japan, 565-0853
- Medical Corporation Heishinkai OCROM Clinic
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan, 160-0008
- Medical Corporation Heishinkai ToCROM Clinic
-
Shinjuku-ku, Tokyo, Japan, 160-0017
- Medical Corporation Shinanokai Shinanozaka Clinic
-
Toshima-ku, Tokyo, Japan, 171-0014
- Sekino Clinical Pharmacology Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who have obtained written consent voluntarily to participate in this clinical trial
- Subjects whose age at the time of obtaining consent is 18 years or older
- Subjects who are negative for SARS-CoV-2 by PCR test
- Subjects who are negative for both SARS-CoV-2 IgM antibody and SARS-CoV-2 IgG antibody by antibody test
Exclusion Criteria:
- Subjects with symptoms of suspected COVID-19 infection (respiratory symptoms, headache, malaise, olfactory disorders, taste disorders, etc.)
- Subjects with a history of COVID-19 (hearing from subjects)
- Subjects with a history of vaccination for the prevention of COVID-19
- Subjects who have participated in unapproved vaccine clinical trials within 1 year before the start of this study
- Subjects with an axillary temperature of 37.5 degrees or higher at the time of screening
- Subjects with an axillary temperature of 37.5 degrees or higher before the first vaccination
- Subjects who have a history of anaphylaxis
- Subjects who have a history of hypersensitivity to the ingredients of the investigational drug
- Subjects who have a current or history of serious renal, cardiovascular, respiratory, liver, kidney, gastrointestinal, and neuropsychiatric diseases
- Subjects with a history of convulsion or epilepsy
- Subjects with a history of diagnosis of immunodeficiency
- Subjects who have a close relative (within 3rd degree) of congenital immunodeficiency
- Subjects who have current bronchial asthma
- Subjects who have had a fever of 39.0 degrees or higher within 2 days after vaccination, or who have been suspected of having an allergy such as a systemic rash.
- Females who wish to become pregnant from the time of obtaining consent to 12 weeks after the first vaccination, and pregnant females who are breast-feeding. In addition, females who may become pregnant and their male sexual partners should use appropriate contraceptives (pill), condoms, vasectomy, tubal ligation, diaphragm, intrauterine devices, spermicides, intrauterine hormone-releasing system, etc. from the study entry date until 12 weeks after the first vaccination
- Subjects who have participated in clinical trials of other unapproved drugs and received the investigational drug within 4 weeks before the start of this clinical trial (starting from vaccination day)
- Subjects who have been received a live vaccine, inactivated vaccine, or toxoid within 4 weeks before the start of this clinical trial (starting from vaccination day)
- Subjects who have been administered with drugs that affect the immune system (excluding external preparations) such as immunomodulators (DMARDs, etc.), immunosuppressants, biologics, etc. within 4 weeks before vaccination
- Subjects who received blood transfusion or gamma globulin therapy within 12 weeks before vaccination, or high-dose gamma globulin therapy (200 mg/kg or more) within 24 weeks before vaccination
- Subjects who have a history of overseas travel within 4 weeks before the start of the clinical trial (starting from vaccination day)
- Subjects who are unable to comply with the clinical trial protocol and follow up (for mental, family, social or geographical reasons)
- Subjects who are judged to be ineligible for this clinical trial by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
|
Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
|
Experimental: Group B
|
Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
|
Experimental: Group C
|
Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
|
Experimental: Group D
|
Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
|
Experimental: Group E
|
Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Week 1 through Week 13
|
Frequency and severity of each adverse event, solicited local and systemic AEs from the first vaccination to 12 weeks after first vaccination
|
Week 1 through Week 13
|
Immunogenicity
Time Frame: Week 13
|
Change in the neutralizing activity against pseudovirus of SARS-CoV-2 [ID50]
|
Week 13
|
Immunogenicity
Time Frame: Week 13
|
Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody
|
Week 13
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of SARS-CoV-2 positive and incidence rate of COVID-19 after the first vaccination
Time Frame: Week 1 through Week 53
|
Week 1 through Week 53
|
Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody
Time Frame: Weeks 5, 7, 9, 13, 17, 21, 25, 37, 53
|
Weeks 5, 7, 9, 13, 17, 21, 25, 37, 53
|
Change in the neutralizing activity against pseudovirus of SARS-CoV-2
Time Frame: Weeks 5, 7, 9, 13, 17, 21, 25, 37, 53
|
Weeks 5, 7, 9, 13, 17, 21, 25, 37, 53
|
Seroconversion rate from baseline (defined as a 4-fold or greater increase) in the neutralizing activity against pseudovirus of SARS-CoV-2 [ID50]
Time Frame: Weeks 5, 7, 9, 13, 17, 21, 25, 37, 53
|
Weeks 5, 7, 9, 13, 17, 21, 25, 37, 53
|
Change in IFN-gamma production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells
Time Frame: Weeks 5, 7, 9, 13
|
Weeks 5, 7, 9, 13
|
IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody
Time Frame: Weeks 1, 9, 13
|
Weeks 1, 9, 13
|
Adverse events
Time Frame: Week 13 through Week 53
|
Week 13 through Week 53
|
Rate of swelling and leakage of the drug to the vaccination site during intradermal vaccination
Time Frame: Weeks 1, 3, 5
|
Weeks 1, 3, 5
|
Number of defects in preparation and vaccination during intradermal vaccination
Time Frame: Week 1 through Week 5
|
Week 1 through Week 5
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Clinical Development, AnGes, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG0302-COVID19-JN-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Lower Respiratory Infection
-
Aga Khan UniversityCompletedCOVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Lower Respiratory InfectionPakistan
-
Tiziana Life Sciences LTDWithdrawnCovid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
-
Ohio UniversityAmerican Osteopathic FoundationCompletedSARS-CoV2 Infection | COVID-19 Lower Respiratory InfectionUnited States
-
Cambridge Health AllianceThe Thoracic Foundation; AlturixNot yet recruitingCovid19 | Oxidative Stress | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Respiratory Infection | SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere | COVID-19 Lower Respiratory InfectionUnited States
-
Instituto Venezolano de Investigaciones CientificasCompletedCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | COVID-19 Lower Respiratory InfectionVenezuela
-
ProgenaBiomeCompletedCovid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | COVID-19 Acute Bronchitis | COVID-19 Lower Respiratory InfectionUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCOVID-19 | Coronavirus Disease 2019 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | COVID-19 Acute Bronchitis | COVID-19 Lower Respiratory InfectionUnited States
-
KARE BiosciencesBiomedical Advanced Research and Development Authority; BioLink Life Sciences... and other collaboratorsRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory InfectionIndia
-
Azienda Ospedaliera Universitaria Integrata VeronaCharite University, Berlin, Germany; Institut National de la Santé Et de la... and other collaboratorsRecruitingCoronavirus Infections | Covid19 | Coronavirus Disease 2019 | Corona Virus Infection | Coronavirus | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | SARS (Severe Acute Respiratory Syndrome) | COVID-19 Respiratory Infection | SARS (Disease) | COVID-19 Acute Respiratory Distress... and other conditionsItaly, Belgium, Congo, France, Netherlands, Spain
-
Catalysis SLCompletedRespiratory Tract Infections | Covid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Viral Infection | Infection, CoronavirusKazakhstan
Clinical Trials on AG0302-COVID19 for Intramuscular Injection
-
AnGes, Inc.Japan Agency for Medical Research and DevelopmentCompleted
-
Emergex Vaccines Holding Ltd.Not yet recruitingCOVID-19 | Coronavirus | SARS-CoV-2 InfectionPhilippines
-
Chumakov Federal Scientific Center for Research...Active, not recruiting
-
Chumakov Federal Scientific Center for Research...CompletedCoronavirus Infections | VaccineRussian Federation
-
Seventh Medical Center of PLA General HospitalActive, not recruiting
-
Universita degli Studi di GenovaIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale...CompletedCovid19 | Hemodialysis Complication | Inflammatory ResponseItaly
-
Royan InstituteUnknown
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
MedicagoActive, not recruitingSARS-CoV-2 InfectionUnited States, Canada, United Kingdom, Argentina, Brazil, Mexico